All In Biotech

Drug Trial Radar · NCT05333835

A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

A 26-week, Randomized, Open-label, 3-arm Parallel, Treat-to-target Study Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin With or Without One Other Oral Anti-diabetic Drug

Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 455 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

455

Actual

Start

Jul 8, 2022

Primary completion

Mar 30, 2024

Study completion Mar 30, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • HR17031 injectionDrug

    HR17031 injection

  • INS068 injectionDrug

    INS068 injection

  • SHR20004 injectionDrug

    SHR20004 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in HbA1c at Week 26Time frame: at Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking university People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.